[{"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Gain of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "NRAS GTPase activity is reduced, hence GTP-binding is increased, leading to the activation of the protein.", "support": "Strong", "comment": null, "references": "PMID:3533068", "annotations": [], "created_on": "2020-10-07T15:28:53.115Z", "last_modified": "2020-10-07T15:29:00.732Z", "status": "unreviewed", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "G12V", "hgvs_c": "NM_002524.4:c.35G>T", "hgvs_p": "NP_002515.1:p.Gly12Val", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115258747, "dbsnp_ids": ["121913237"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["temozolomide"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Case reports", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Soon et al. studied one melanoma patient with a tumor bearing NRAS Q61K . The patient was treated with temozolomide and showed disease stabilization after two cycles, then progression.", "support": "Low", "comment": null, "references": "PMID:21576590", "annotations": [], "created_on": "2020-10-12T16:38:19.415Z", "last_modified": "2020-10-12T16:43:56.630Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Binimetinib"], "interactions": [], "effect": "Responsive", "tier_level_criteria": "Clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In a phase 2 study, Ascierto et al. reported that 6 (20%) of 30 patients with NRAS-mutated melanoma had a partial response to binimetinib/MEK162, 3 of which have been confirmed. In this panel of studied patients, 30% were bearing Q61K variant, but it is not specified what is the genotype of the tumors that responded to treatment.", "support": "Low", "comment": null, "references": "PMID:23414587", "annotations": [], "created_on": "2020-09-23T08:21:26.431Z", "last_modified": "2020-10-09T16:07:09.213Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Ascierto et al. identified variant Q61K in 9 melanoma patient out of 27 (33%).", "support": "Strong", "comment": null, "references": "PMID:23414587", "annotations": [], "created_on": "2020-09-23T08:03:46.186Z", "last_modified": "2020-10-09T16:06:06.315Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Binimetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of  Q61K-bearing neuroblastoma cell lines CHP-212 and SK-N-AS with binimetinib/MEK162 resulted in dose-dependent growth inhibition. In these cell lines, binimetinib may induce cell death.", "support": "Low", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-04T16:03:46.878Z", "last_modified": "2020-10-09T13:15:18.574Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Gain of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "NRAS GTPase activity is reduced, hence GTP-binding is increased, leading to the activation of the protein.", "support": "Strong", "comment": null, "references": "PMID:3533068", "annotations": [], "created_on": "2020-10-07T15:28:25.656Z", "last_modified": "2020-10-07T15:29:08.585Z", "status": "unreviewed", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Function", "drugs": [], "interactions": [], "effect": "Gain of function", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Strong increase in activated NRAS-GTPase.", "support": "Strong", "comment": "", "references": "PMID:22773810", "annotations": [], "created_on": "2020-10-02T10:56:47.294Z", "last_modified": "2020-10-07T14:29:26.080Z", "status": "unreviewed", "request_id": null, "disease": null, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Romano et al. studied metastases from a young patient with BRAF V600E-bearing cutaneous melanoma, that responded to an initial treatment with vemurafenib, eventually progressed. The patient then received four cycles of ipilimumab followed by two cycles of temozolomide, and one cycle of fotemustine with progression of disease and the appearance of new lesions. He was successfully rechallenged with vemurafenib and then progressed again. A subcutaneous metastasis (PV1) present at baseline, completely responded to first vemurafenib treatment, then reappeared and progressed during chemotherapy, responded again (partially) with second vemurafenib treatment, then progressed. This metastasis was harboring 2 NRAS mutations: Q61K and Q61R, but in different cells. These mutations were not found in the pretreatment tumor.", "support": "Strong", "comment": null, "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T13:55:30.447Z", "last_modified": "2020-10-06T14:56:35.136Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Case reports", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Romano et al. studied metastases from a young patient with BRAF V600E-bearing cutaneous melanoma, that responded to an initial treatment with vemurafenib, eventually progressed. The patient then received four cycles of ipilimumab followed by two cycles of temozolomide, and one cycle of fotemustine with progression of disease and the appearance of new lesions. He was successfully rechallenged with vemurafenib and then progressed again. A subcutaneous metastasis (PV1) present at baseline, completely responded to first vemurafenib treatment, then reappeared and progressed during chemotherapy, responded again (partially) with second vemurafenib treatment, then progressed. This metastasis was harboring 2 NRAS mutations: Q61K and Q61R, but in different cells. These mutations were not found in the pretreatment tumor.", "support": "Moderate", "comment": null, "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T14:08:23.669Z", "last_modified": "2020-10-06T14:56:31.158Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Cells derived from a subcutaneous metastasis from a patient with BRAF V600E-bearing melanoma, which acquired new NRAS mutations Q61K and Q61R, were resistant to vemurafenib in cell culture experiments.", "support": "Moderate", "comment": "", "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T14:15:49.841Z", "last_modified": "2020-10-06T14:56:27.653Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Response to drug", "drugs": ["PD184352"], "interactions": [], "effect": "Newly acquired drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Cells derived from a subcutaneous metastasis from a patient with BRAF V600E-bearing melanoma, which acquired new NRAS mutations Q61K and Q61R, were resistant to vemurafenib, but sensitive to PD184352/CI-1040 (IUPAC name:2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide) in cell culture experiments.", "support": "Moderate", "comment": "", "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T14:22:27.916Z", "last_modified": "2020-10-06T14:55:52.294Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Cells derived from a subcutaneous metastasis from a patient with BRAF V600E-bearing melanoma, which acquired new NRAS mutations Q61K and Q61R, were resistant to vemurafenib, but sensitive to selumetinib in cell culture experiments.", "support": "Moderate", "comment": "", "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T14:18:15.632Z", "last_modified": "2020-10-06T14:55:48.365Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["trametinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "2 non-small cell lung carcinoma cell lines (H1299 andH2087) exhibit decreased growth when treated with trametinib. The third cell line tested (HCC15) did not respond in terms of cell growth.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:49:06.236Z", "last_modified": "2020-10-05T09:01:53.052Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["SGX-523"], "interactions": [], "effect": "Loss of drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 non-small cell lung carcinoma cell lines (H1299, H2087 and HCC15) did not show any growth inhibition when treated with SGX-523 (IUPAC name: 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline).", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:51:52.085Z", "last_modified": "2020-10-05T09:01:48.027Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "2 non-small cell lung carcinoma cell lines (H1299 andH2087) exhibit decreased growth when treated with selumetinib. The third cell line tested (HCC15) did not respond in terms of cell growth.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:48:12.363Z", "last_modified": "2020-10-05T09:01:40.838Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Pictilisib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 non-small cell lung carcinoma cell lines (H1299, H2087 and HCC15) did not show any growth inhibition when treated with pictilisib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:39:12.192Z", "last_modified": "2020-10-05T09:00:08.037Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 non-small cell lung carcinoma cell lines (H1299, H2087 and HCC15) did not show any growth inhibition when treated with vemurafenib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:38:14.709Z", "last_modified": "2020-10-05T09:00:03.039Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Linsitinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 non-small cell lung carcinoma cell lines (H1299, H2087 and HCC15) did not show any growth inhibition when treated with linsitinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:37:44.096Z", "last_modified": "2020-10-05T08:59:55.859Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["crizotinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 non-small cell lung carcinoma cell lines (H1299, H2087 and HCC15) did not show any growth inhibition when treated with crizotinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:33:43.158Z", "last_modified": "2020-10-05T08:59:51.671Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["erlotinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 non-small cell lung carcinoma cell lines (H1299, H2087 and HCC15) did not show any growth inhibition when treated with erlotinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:27:30.732Z", "last_modified": "2020-10-05T08:59:45.283Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Ohashi et al. identified 3 non-small cell lung cancers (NSCLC) carrying NRAS Q61K out of 4'562. There was no significant correlation with NRAS mutations and gender, histology, or clinical stage, but there was a significant association of NRAS mutations with smoking history. The growth of a lung cancer cell line carrying NRAS Q61K (H1299) was dependent upon NRAS, as NRAS silencing impaired growth.", "support": null, "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:01:19.530Z", "last_modified": "2020-10-05T08:59:38.306Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["erlotinib", "Selumetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The growth of an erlotinib-resistant cell line derived from the 11-18 cell line, bearing EGFR L858R and NRAS Q61K mutations, was decreased by treatment with a combination of selumetinib and erlotinib, but not  selumetinib alone.", "support": "Moderate", "comment": "I have randomly picked up the HGVS expression for the EGFR mutation L858R, as there are at 4 possible changes that have the same effect at the amino acid level (c.2573T>G, c.2573_2574TG>GT, c.2573_2574TG>GA, c.2572_2573CT>AG) and the authors don't provide any information on this subject and I didn't find it on the web for this cell line.", "references": "PMID:22773810", "annotations": [], "created_on": "2020-10-02T11:08:31.806Z", "last_modified": "2020-10-02T12:05:13.316Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "EGFR", "name": "L858R", "hgvs_c": "NM_005228.3:c.2573T>G"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Trametinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The growth of an erlotinib-resistant cell line derived from the 1-18 cell line, bearing EGFR L858R and NRAS Q61K mutations, was not affected by treatment with trametinib in culture. Similar results were observed when 11-18R cells were grown in athymic nude mice.", "support": "Moderate", "comment": "I have randomly picked up the HGVS expression for the EGFR mutation L858R, as there are at 4 possible changes that have the same effect at the amino acid level (c.2573T>G, c.2573_2574TG>GT, c.2573_2574TG>GA, c.2572_2573CT>AG) and the authors don't provide any information on this subject and I didn't find it on the web for this cell line.", "references": "PMID:22773810", "annotations": [], "created_on": "2020-10-02T11:19:43.944Z", "last_modified": "2020-10-02T12:04:35.695Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "EGFR", "name": "L858R", "hgvs_c": "NM_005228.3:c.2573T>G"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["erlotinib", "Trametinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The growth of an erlotinib-resistant cell line derived from the 11-18 cell line, bearing EGFR L858R and NRAS Q61K mutations, was decreased by treatment with a combination of trametinib and erlotinib, but not  trametinib alone. Similar results were observed when 11-18R cells were grown in athymic nude mice.", "support": "Moderate", "comment": "I have randomly picked up the HGVS expression for the EGFR mutation L858R, as there are at 4 possible changes that have the same effect at the amino acid level (c.2573T>G, c.2573_2574TG>GT, c.2573_2574TG>GA, c.2572_2573CT>AG) and the authors don't provide any information on this subject and I didn't find it on the web for this cell line.", "references": "PMID:22773810", "annotations": [], "created_on": "2020-10-02T11:17:52.208Z", "last_modified": "2020-10-02T12:02:58.897Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "EGFR", "name": "L858R", "hgvs_c": "NM_005228.3:c.2573T>G"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The growth of an erlotinib-resistant cell line derived from the 1-18 cell line, bearing EGFR L858R and NRAS Q61K mutations, was not affected by treatment with selumetinib in culture.", "support": "Moderate", "comment": "I have randomly picked up the HGVS expression for the EGFR mutation L858R, as there are at 4 possible changes that have the same effect at the amino acid level (c.2573T>G, c.2573_2574TG>GT, c.2573_2574TG>GA, c.2572_2573CT>AG) and the authors don't provide any information on this subject and I didn't find it on the web for this cell line.", "references": "PMID:22773810", "annotations": [], "created_on": "2020-10-02T11:05:09.731Z", "last_modified": "2020-10-02T12:01:57.767Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "EGFR", "name": "L858R", "hgvs_c": "NM_005228.3:c.2573T>G"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["erlotinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The authors developed an erlotinib-resistant cell line derived from the lung adenocarcinoma 11-18 cell line and observed that resistance to erlotinib was accompanied by the new acquisition of NRAS Q61K mutation. Similar results were observed when 11-18R cells were grown in athymic nude mice. NRAS protein knockdown in these cells led to an increased response to erlotinib. Conversely ectopic expression of NRAS Q61K confered  erlotinib resistance to cells harboring drug-Sensitive EGFR mutations. NRAS Q61K was not detected in 212 samples from patients with EGFR-mutant lung cancer and acquired resistance to EGFR TKIs, suggesting it a rare variant in this context.", "support": "Strong", "comment": "I have randomly picked up the HGVS expression for the EGFR mutation L858R, as there are at 4 possible changes that have the same effect at the amino acid level (c.2573T>G, c.2573_2574TG>GT, c.2573_2574TG>GA, c.2572_2573CT>AG) and the authors don't provide any information on this subject and I didn't find it on the web for this cell line.", "references": "PMID:22773810", "annotations": [], "created_on": "2020-10-02T09:49:54.661Z", "last_modified": "2020-10-02T12:01:18.827Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "EGFR", "name": "L858R", "hgvs_c": "NM_005228.3:c.2573T>G"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Transfection of a melanoma-derived cell line carrying BRAF V600E with NRAS Q61K induced resistance to vemurafenib.", "support": "Low", "comment": null, "references": "PMID:22395615", "annotations": [], "created_on": "2020-10-02T08:25:06.195Z", "last_modified": "2020-10-02T08:38:07.778Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "In one melanoma patient, whose BRAF V600E tumor was resistant to vemurafenib/PLX4032, Nazarian et al. found a newly acquired NRAS Q61K mutation. Stable NRAS knockdown restored sensitivity to vemurafenib in a cell line derived from the tumor, while NRAS Q61K stable overexpression conferred vemurafenib resistance in the parental cell line, that did not bear the mutation.  These observation suggest that BRAF V600E-positive melanomas can acquire vemurafenib resistance by reactivating the MAPK pathway via NRAS upregulation. The very same cell line was studied by Shi et al., 2012 (PMID:22395615), who confirmed resistance to vemurafenib.", "support": "Low", "comment": null, "references": "PMID:21107323", "annotations": [], "created_on": "2020-09-29T16:31:39.813Z", "last_modified": "2020-10-02T08:37:53.882Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "In one melanoma patient, whose BRAF V600E tumor was resistant to vemurafenib/PLX4032, Nazarian et al. found a newly acquired NRAS Q61K mutation. Treatment of a cell line derived from this tumor was sensitive to selumetinib/AZD6244 in the presence or in the absence of vemurafenib/PLX4032.  The very same cell line was studied by Shi et al., 2012 (PMID:22395615), who confirmed sensitivity to selumetinib.", "support": "Low", "comment": null, "references": "PMID:21107323", "annotations": [], "created_on": "2020-09-29T16:37:48.329Z", "last_modified": "2020-10-02T08:37:42.385Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib", "Dactolisib", "Cetuximab"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 colorectal cancers bearing the NRAS Q61K mutation were implanted in NOD/SCID mice. Animals were treated with a combination selumetinib/AZD6244, dactolisib/BEZ235 and cetuximab. For 2 out of 3 tumors, the treatment did not affect tumor growth; the third tumor showed very limited growth, but no regression. The growth-inhibitory effect, if any, was not sufficient to fully contrast residual tumor cell proliferation and failed to induce prolonged overall benefit.", "support": "Low", "comment": null, "references": "PMID:22392911", "annotations": [], "created_on": "2020-09-30T15:03:44.710Z", "last_modified": "2020-09-30T16:20:00.101Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 colorectal cancers bearing the NRAS Q61K mutation were implanted in NOD/SCID mice. Animals were treated with selumetinib/AZD6244. The treatment did not affect tumor growth.", "support": "Low", "comment": null, "references": "PMID:22392911", "annotations": [], "created_on": "2020-09-30T14:33:03.656Z", "last_modified": "2020-09-30T15:41:07.340Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Dactolisib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 colorectal cancers bearing the NRAS Q61K mutation were implanted in NOD/SCID mice. Animals were treated with dactolisib/BEZ235. For 2 out of 3 tumors, the treatment did not affect tumor growth; the third tumor showed limited growth, but no regression. The growth-inhibitory effect, if any, was not sufficient to fully contrast residual tumor cell proliferation and failed to induce prolonged overall benefit.", "support": "Low", "comment": null, "references": "PMID:22392911", "annotations": [], "created_on": "2020-09-30T15:01:03.797Z", "last_modified": "2020-09-30T15:41:01.196Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib", "Dactolisib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "3 colorectal cancers bearing the NRAS Q61K mutation were implanted in NOD/SCID mice. Animals were treated with a combination selumetinib/AZD6244 and dactolisib/BEZ235. For 2 out of 3 tumors, the treatment did not affect tumor growth; the third tumor showed very limited growth, but no regression. The growth-inhibitory effect, if any, was not sufficient to fully contrast residual tumor cell proliferation and failed to induce prolonged overall benefit.", "support": "Low", "comment": null, "references": "PMID:22392911", "annotations": [], "created_on": "2020-09-30T15:01:00.781Z", "last_modified": "2020-09-30T15:40:55.623Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 2 melanoma cell lines, , the presence of NRAS Q61K, in addition to the BRAF V600E mutation, was associated with resistance to vemurafenib.", "support": "Low", "comment": null, "references": "PMID:22194965", "annotations": [], "created_on": "2020-09-30T09:33:11.150Z", "last_modified": "2020-09-30T09:37:21.315Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In 2 melanoma cell lines, , the presence of NRAS Q61K, in addition to the BRAF V600E mutation, was associated with resistance to vemurafenib, but sensitivity to selumetinib/AZD6244 in vitro.", "support": "Low", "comment": null, "references": "PMID:22194965", "annotations": [], "created_on": "2020-09-30T09:37:16.112Z", "last_modified": "2020-09-30T09:37:16.113Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["dabrafenib", "trametinib"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Case reports", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Long et al. studied mutant melanoma patients who had early resistance to combined BRAF (dabrafenib) and MEK (trametinib) inhibitor therapy. In one tumor sample that was carrying BRAF V600K, they could shown that resistance could be due to a newly acquired  NRAS Q61K mutation.", "support": "Low", "comment": "", "references": "PMID:25452114", "annotations": [], "created_on": "2020-09-28T14:39:47.147Z", "last_modified": "2020-09-30T08:24:46.098Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600K", "hgvs_c": "NM_004333.4:c.1798_1799delGTinsAA"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["dabrafenib", "trametinib"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Case reports", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Long et al. studied mutant melanoma patients who had early resistance to combined BRAF (dabrafenib) and MEK (trametinib) inhibitor therapy. In one tumor sample that was carrying BRAF V600K, they could shown that resistance could be due to newly acquired  NRAS Q61K mutation and BRAF gene amplification.", "support": "Low", "comment": "", "references": "PMID:25452114", "annotations": [], "created_on": "2020-09-28T14:41:57.159Z", "last_modified": "2020-09-30T08:24:24.013Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600K", "hgvs_c": "NM_004333.4:c.1798_1799delGTinsAA"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Buparlisib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of  Q61K-bearing neuroblastoma cell lines CHP-212 and SK-N-AS with buparlisib/BKM120 had no effect on cell growth, nor did it affect binimetinib/MEK162-induced cell growth inhibition.", "support": "Low", "comment": "", "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-07T09:36:54.931Z", "last_modified": "2020-09-07T10:28:00.856Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Everolimus"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of  Q61K-bearing neuroblastoma cell lines CHP-212 and SK-N-AS with everolimus resulted in dose-dependent growth inhibition and induction of apoptosis. This effect was specific to NRAS-mutated cells, as wild-type NRAS cells did not exhibit any deleterious phenotype.", "support": "Low", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-07T10:00:12.892Z", "last_modified": "2020-09-07T10:27:55.407Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["AZD8055"], "interactions": [], "effect": "Increased drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of  Q61K-bearing neuroblastoma cell lines CHP-212 and SK-N-AS with mTOR kinase inhibitor AZD8055 resulted in dose-dependent growth inhibition. However, it should be noted that this effect was also observed in NRAS wild-type cell lines, though to a lesser extent than in NRAS Q61K cell lines", "support": "Low", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-07T10:05:40.789Z", "last_modified": "2020-09-07T10:27:50.798Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Everolimus", "Binimetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of  Q61K-bearing neuroblastoma cell line CHP-212 with a combination of everolimus and binimetinib/MEK162 resulted in dose-dependent growth inhibition, at a much higher level than for both compounds applied separately. Both drugs may act synergistically.", "support": "Low", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-07T10:12:48.283Z", "last_modified": "2020-09-07T10:27:43.971Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["GSK690693"], "interactions": [], "effect": "Other", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of  Q61K-bearing neuroblastoma cell lines CHP-212 and SK-N-AS with the aminofurazan-derived Akt kinase inhibitor GSK690693 had no effect on cell growth, nor did it affect binimetinib/MEK162-induced cell growth inhibition.", "support": "Low", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-07T09:42:59.085Z", "last_modified": "2020-09-07T10:27:27.268Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib", "Everolimus"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of  Q61K-bearing neuroblastoma cell lines CHP-212 and SK-N-AS with a combination of everolimus and selumetinib/AZD6244 resulted in dose-dependent growth inhibition, at a much higher level than for both compounds applied separately. Both drugs may act synergistically.", "support": "Low", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-07T10:15:25.782Z", "last_modified": "2020-09-07T10:27:20.885Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["AZD8055", "Binimetinib"], "interactions": [], "effect": "Increased drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of  Q61K-bearing neuroblastoma cell lines CHP-212 and SK-N-AS with a combination of mTOR kinase inhibitor AZD8055 and binimetinib/MEK162 resulted in dose-dependent growth inhibition, at a much higher level than for both compounds applied separately. Both drugs may act synergistically.", "support": "Low", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-07T10:27:16.496Z", "last_modified": "2020-09-07T10:27:16.496Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The authors observed dose-dependent growth inhibition of Q61K-bearing neuroblastoma cell lines CHP-212 and SK-N-AS treated with selumetinib/AZD6244.", "support": "Low", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-04T16:01:37.970Z", "last_modified": "2020-09-07T09:24:17.501Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Mirdametinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The authors observed dose-dependent growth inhibition of Q61K-bearing neuroblastoma cell lines CHP-212 and SK-N-AS treated with mirdametinib/PD0301925.", "support": "Low", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-04T16:05:25.567Z", "last_modified": "2020-09-07T09:23:47.289Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Out of 799 neuroblastoma tested, Kiessling et al. identified 3 tumors bearing NRAS Q61K, 2 of them originated from high-risk patients et one from intermediate risk.", "support": "Strong", "comment": null, "references": "PMID:26821351", "annotations": [], "created_on": "2020-09-04T15:54:44.437Z", "last_modified": "2020-09-04T16:05:34.411Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neuroblastoma", "localization": null, "user_created": true}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Cetuximab"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "De Roock et al.  carried out a retrospective study on 773 tumor samples from metastatic colorectal cancer patients. NRAS mutations, including Q61K, were identified. Patients were treated with cetuximab in combination with chemotherapy. Compared with wild types, NRAS mutations were significantly associated with lower response and disease control rates, and shorter overall survival, whereas no significant difference in  progression-free survival was seen. Of note, NRAS and KRAS mutations were mutually exclusive, as well as NRAS and BRAF, therefore Q61K tumors in this study carried wild-type KRAS and BRAF.", "support": "Moderate", "comment": "", "references": "PMID:20619739", "annotations": [], "created_on": "2020-09-04T14:45:16.026Z", "last_modified": "2020-09-04T14:45:16.027Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "De Roock et al.  identified NRAS Q61K variant in a panel of colorectal cancer tumors. In these samples, NRAS and BRAF mutations were mutually exclusive, as well as NRAS and KRAS.", "support": "Strong", "comment": null, "references": "PMID:20619739", "annotations": [], "created_on": "2020-09-04T14:24:13.709Z", "last_modified": "2020-09-04T14:45:07.376Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61K", "hgvs_c": "NM_002524.4:c.181C>A", "hgvs_p": "NP_002515.1:p.Gln61Lys", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256530, "dbsnp_ids": ["121913254"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["PLX4720"], "interactions": [], "effect": "Other", "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Treatment of the NRAS Q61R-bearing thyroid carcinoma HTH7  cell line with PLX4720 did not impair cell growth, nor affect MAPK/ERK pathway activity. The treatment seemed cytostatic rather than cytotoxic. PLX4720 is a derivative of vemurafenib, in which vemurafenib p-chlorophenyl group has been replaced by chlorine. IUPAC name: N-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]propane-1-sulfonamide.", "support": "Low", "comment": null, "references": "PMID:19880792", "annotations": [], "created_on": "2020-10-13T15:39:16.533Z", "last_modified": "2020-10-13T16:27:55.169Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neoplasm of thyroid gland", "localization": "THYROID", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Vemurafenib treatment of the NRAS Q61R-bearing thyroid carcinoma HTH7  cell line did not impair cell growth, nor affect MAPK/ERK  pathway activity.", "support": "Low", "comment": null, "references": "PMID:19880792", "annotations": [], "created_on": "2020-10-13T15:32:45.753Z", "last_modified": "2020-10-13T16:27:36.197Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Neoplasm of thyroid gland", "localization": "THYROID", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["temozolomide"], "interactions": [], "effect": "Responsive", "tier_level_criteria": "Case reports", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Soon et al. studied the response of 4 melanoma patients with tumors bearing NRAS Q61R to temozolomide: two patients did not respond, one showed disease stabilization after two cycles, then progression and one showed a partial response after 2 treatment cycles and  further improvement after four additional cycles,  resulting in overall survival of 16 months.", "support": "Low", "comment": null, "references": "PMID:21576590", "annotations": [], "created_on": "2020-10-12T16:36:04.947Z", "last_modified": "2020-10-12T16:51:28.286Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Ascierto et al. identified variant Q61R in 15 melanoma patient out of 27 (56%).", "support": "Strong", "comment": null, "references": "PMID:23414587", "annotations": [], "created_on": "2020-09-23T08:03:49.017Z", "last_modified": "2020-10-09T16:06:32.534Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Case reports", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Romano et al. studied metastases from a young patient with BRAF V600E-bearing cutaneous melanoma, that responded to an initial treatment with vemurafenib, eventually progressed. The patient then received four cycles of ipilimumab followed by two cycles of temozolomide, and one cycle of fotemustine with progression of disease and the appearance of new lesions. He was successfully rechallenged with vemurafenib and then progressed again. A subcutaneous metastasis (PV1) present at baseline, completely responded to first vemurafenib treatment, then reappeared and progressed during chemotherapy, responded again (partially) with second vemurafenib treatment, then progressed. This metastasis was harboring 2 NRAS mutations: Q61K and Q61R, but in different cells. These mutations were not found in the pretreatment tumor.", "support": "Moderate", "comment": null, "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T14:08:18.524Z", "last_modified": "2020-10-06T14:56:17.411Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Romano et al. studied metastases from a young patient with BRAF V600E-bearing cutaneous melanoma, that responded to an initial treatment with vemurafenib, eventually progressed. The patient then received four cycles of ipilimumab followed by two cycles of temozolomide, and one cycle of fotemustine with progression of disease and the appearance of new lesions. He was successfully rechallenged with vemurafenib and then progressed again. A subcutaneous metastasis (PV1) present at baseline, completely responded to first vemurafenib treatment, then reappeared and progressed during chemotherapy, responded again (partially) with second vemurafenib treatment, then progressed. This metastasis was harboring 2 NRAS mutations: Q61K and Q61R, but in different cells. These mutations were not found in the pretreatment tumor.", "support": "Strong", "comment": null, "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T13:56:03.921Z", "last_modified": "2020-10-06T14:56:07.412Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Cells derived from a subcutaneous metastasis from a patient with BRAF V600E-bearing melanoma, which acquired new NRAS mutations Q61K and Q61R, were resistant to vemurafenib in cell culture experiments.", "support": "Moderate", "comment": "", "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T14:16:20.844Z", "last_modified": "2020-10-06T14:56:03.330Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Cells derived from a subcutaneous metastasis from a patient with BRAF V600E-bearing melanoma, which acquired new NRAS mutations Q61K and Q61R, were resistant to vemurafenib, but sensitive to selumetinib in cell culture experiments.", "support": "Moderate", "comment": "", "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T14:18:42.049Z", "last_modified": "2020-10-06T14:55:59.659Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Response to drug", "drugs": ["PD184352"], "interactions": [], "effect": "Newly acquired drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": "Somatic", "associated_mendelian_diseases": null, "summary": "Cells derived from a subcutaneous metastasis from a patient with BRAF V600E-bearing melanoma, which acquired new NRAS mutations Q61K and Q61R, were resistant to vemurafenib, but sensitive to PD184352/CI-1040 (IUPAC name:2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide) in cell culture experiments.", "support": "Moderate", "comment": "", "references": "PMID:23948972", "annotations": [], "created_on": "2020-10-06T14:23:48.638Z", "last_modified": "2020-10-06T14:55:56.218Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": [{"gene__symbol": "BRAF", "name": "V600E", "hgvs_c": "NM_004333.4:c.1799T>A"}]}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["crizotinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The non-small cell lung carcinoma cell line H2347 did not show any growth inhibition when treated with crizotinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:35:56.632Z", "last_modified": "2020-10-05T08:55:05.088Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["erlotinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The non-small cell lung carcinoma cell line H2347 did not show any growth inhibition when treated with erlotinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:53:46.463Z", "last_modified": "2020-10-05T08:54:50.164Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["SGX-523"], "interactions": [], "effect": "Loss of drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The non-small cell lung carcinoma cell line H2347 did not show any growth inhibition when treated with SGX-523 (IUPAC name: 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline).", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:01:36.200Z", "last_modified": "2020-10-05T08:53:44.081Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Linsitinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The non-small cell lung carcinoma cell line H2347 did not show any growth inhibition when treated with linsitinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:03:59.472Z", "last_modified": "2020-10-05T08:53:22.377Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The non-small cell lung carcinoma cell line H2347 did not show any growth inhibition when treated with vemurafenib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:05:34.695Z", "last_modified": "2020-10-05T08:52:57.482Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Pictilisib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The non-small cell lung carcinoma cell line H2347 did not show any growth inhibition when treated with pictilisib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:07:24.298Z", "last_modified": "2020-10-05T08:52:27.041Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["crizotinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The small cell lung carcinoma cell line SW1271 did not show any growth inhibition when treated with crizotinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:44:55.753Z", "last_modified": "2020-10-05T08:50:47.263Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Small cell carcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["erlotinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The small cell lung carcinoma cell line SW1271 did not show any growth inhibition when treated with erlotinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:54:28.115Z", "last_modified": "2020-10-05T08:50:04.952Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Small cell carcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Response to drug", "drugs": ["SGX-523"], "interactions": [], "effect": "Loss of drug response", "tier_level_criteria": "Well-established in vitro study", "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The small cell lung carcinoma cell line SW1271 did not show any growth inhibition when treated with SGX-523 (IUPAC name: 6-[[6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]quinoline).", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:02:13.436Z", "last_modified": "2020-10-05T08:36:44.296Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Small cell carcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Linsitinib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The small cell lung carcinoma cell line SW1271 did not show any growth inhibition when treated with linsitinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:04:31.048Z", "last_modified": "2020-10-05T08:36:25.760Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Small cell carcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["vemurafenib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The small cell lung carcinoma cell line SW1271 did not show any growth inhibition when treated with vemurafenib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:06:22.066Z", "last_modified": "2020-10-05T08:35:54.831Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Small cell carcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Pictilisib"], "interactions": [], "effect": "Resistant (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The small cell lung carcinoma cell line SW1271 did not show any growth inhibition when treated with pictilisib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:07:48.823Z", "last_modified": "2020-10-05T08:32:18.311Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Small cell carcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The non-small cell lung carcinoma cell line H2347 exhibited decreased growth when treated with selumetinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:09:14.659Z", "last_modified": "2020-10-05T08:31:35.429Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Selumetinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The small cell lung carcinoma cell line SW1271 exhibited very strong decrease in growth when treated with selumetinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:10:14.102Z", "last_modified": "2020-10-05T08:30:50.881Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Small cell carcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["trametinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The non-small cell lung carcinoma cell line H2347 exhibited growth inhibition when treated with trametinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:12:18.029Z", "last_modified": "2020-10-05T08:30:39.248Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["trametinib"], "interactions": [], "effect": "Sensitive (in vitro)", "tier_level_criteria": "Pre-clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "The small cell lung carcinoma cell line SW1271 exhibited growth inhibition when treated with trametinib.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T14:12:46.107Z", "last_modified": "2020-10-05T08:30:11.220Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Small cell carcinoma of lung", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "Ohashi et al. identified 5 non-small cell lung cancers (NSCLC) carrying NRAS Q61R out of 4'562. There was no significant correlation with NRAS mutations and gender, histology, or clinical stage, but there was a significant association of NRAS mutations with smoking history.", "support": "Moderate", "comment": null, "references": "PMID:23515407", "annotations": [], "created_on": "2020-10-02T13:00:55.620Z", "last_modified": "2020-10-02T13:15:22.243Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Non-small cell lung cancer", "localization": "LUNG", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Binimetinib"], "interactions": [], "effect": "Responsive", "tier_level_criteria": "Clinical trial", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "In a phase 2 study, Ascierto et al. reported that 6 (20%) of 30 patients with NRAS-mutated melanoma had a partial response to binimetinib/MEK162, 3 of which have been confirmed. In this panel of studied patients, 50% were bearing Q61R variant, but it is not specified what is the genotype of the tumors that responded to treatment.", "support": "Low", "comment": null, "references": "PMID:23414587", "annotations": [], "created_on": "2020-09-23T08:21:29.491Z", "last_modified": "2020-09-23T09:29:34.827Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Malignant melanoma of skin", "localization": "SKIN", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Predictive / Therapeutic", "drugs": ["Cetuximab"], "interactions": [], "effect": "Not responsive", "tier_level_criteria": "Population study", "tier_level": "Tier IID", "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "De Roock et al.  carried out a retrospective study on 773 tumor samples from metastatic colorectal cancer patients. NRAS mutations, including Q61R, were identified. Patients were treated with cetuximab in combination with chemotherapy. Compared with wild types, NRAS mutations were significantly associated with lower response and disease control rates, and shorter overall survival, whereas no significant difference in  progression-free survival was seen. Of note, NRAS and KRAS mutations were mutually exclusive, as well as NRAS and BRAF, therefore Q61R tumors in this study carried wild-type KRAS and BRAF.", "support": "Moderate", "comment": null, "references": "PMID:20619739", "annotations": [], "created_on": "2020-09-04T14:45:35.883Z", "last_modified": "2020-09-04T14:45:35.883Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}, {"type_of_evidence": "Variant identification", "drugs": [], "interactions": [], "effect": null, "tier_level_criteria": null, "tier_level": null, "mutation_origin": null, "associated_mendelian_diseases": null, "summary": "De Roock et al.  identified NRAS Q61R variant in a panel of colorectal cancer tumors. In these samples, NRAS and BRAF mutations were mutually exclusive, as well as NRAS and KRAS.", "support": "Strong", "comment": null, "references": "PMID:20619739", "annotations": [], "created_on": "2020-09-04T14:44:27.613Z", "last_modified": "2020-09-04T14:45:28.001Z", "status": "unreviewed", "request_id": null, "disease": {"name": "Adenocarcinoma of colorectum", "localization": "COLON", "user_created": false}, "owner": {"username": "anne_estreicher", "first_name": "Anne", "last_name": "Estreicher", "email": ""}, "variant": {"gene__symbol": "NRAS", "name": "Q61R", "hgvs_c": "NM_002524.4:c.182A>G", "hgvs_p": "NP_002515.1:p.Gln61Arg", "reference_name": "GRCh37", "chromosome": "1", "start_pos": 115256529, "dbsnp_ids": ["11554290"]}, "extra_variants": []}]